August 4, 2017

Neratinib FDA Approval for Extended Adjuvant Therapy a Win for HER2+ Patients

Safe, effective, welcome option

abraham_650x450

By Jame Abraham, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The recent FDA approval of neratinib for extended adjuvant treatment of early-state, HER2-positive breast cancer is good news for many patients. I’ve been involved with the development of this therapy by being part of many clinical trials over the past seven years. Early studies in metastatic breast cancer have shown that neratinib is a very active HER2 blocker and has synergy with other HER2 targeted medicines such as trastuzumab. In addition, the most recent FDA approval is a testament of its efficacy in improving disease-free survival in high risk HER2-positive patients after one year of trastuzumab.

Neratinib is an irreversible tyrosine kinase inhibitor (TKI) that interrupts signaling across the ErbB family by inhibiting phosphorylation and activity of HER2, in addition to epidermal growth factor, HER1 and HER4. We recently showed neratinib’s promise in a combination therapy trial with trastuzumab ematansine (T-DM1). The results I presented at the 2017 American Association for Cancer Research meeting showed an objective response rate of 56 percent in patients with advanced, HER2-positive breast cancer and resistance to trastuzumab and pertuzumab. We are expanding this study into more centers and enrolling more patients in a phase 2 study (NSABP FB 10).

The overall role of neratinib in the management of breast cancer is evolving. I think the FDA’s approval for extended adjuvant treatment is a positive indication that this drug will be an important part of the treatment landscape for many years to come.

Advertisement

Dr. Abraham is Director of the Breast Oncology Program at Cleveland Clinic Cancer Center.

Related Articles

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad